Sandhill Capital Partners’s Gain Therapeutics GANX Stock Holding History

Sandhill Capital Partners’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31.3K	Hold	15,400	–	–	﹤0.01%	96
2026 Q1	$29.9K	Hold	15,400	–	–	﹤0.01%	95
2025 Q4	$49.6K	Hold	15,400	–	–	﹤0.01%	104
2025 Q3	$27.3K	Hold	15,400	–	–	﹤0.01%	105
2025 Q2	$27.7K	Hold	15,400	–	–	﹤0.01%	97
2025 Q1	$29.4K	Hold	15,400	–	–	﹤0.01%	88
2024 Q4	$33.3K	Hold	15,400	–	–	﹤0.01%	92
2024 Q3	$27.4K	Buy	+15,400	New	+$19.4K	﹤0.01%	90

Other funds holding GANX

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

PCM

Potomac Capital Management New York $147M AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

DCM

DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Sandhill Capital Partners's GANX Position: Q2 2026 in Review

Sandhill Capital Partners held its Gain Therapeutics (GANX) position steady in Q2 2026 at 15,400 shares worth $31.3K. The position accounts for ﹤0.01% of the portfolio, ranked #96.

Sandhill Capital Partners first reported a position in GANX in Q3 2024 and has held it in 8 quarters since. The position peaked at $49.6K in Q4 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

Sandhill Capital Partners held 15,400 shares of Gain Therapeutics worth $31.3K as of Q2 2026.
Sandhill Capital Partners left its Gain Therapeutics share count unchanged in Q2 2026.
Gain Therapeutics made up ﹤0.01% of Sandhill Capital Partners's portfolio in Q2 2026, its #96 holding.
Sandhill Capital Partners first reported a position in Gain Therapeutics in Q3 2024 and has held it in 8 quarters since.
Sandhill Capital Partners's Gain Therapeutics position peaked at $49.6K in Q4 2025.
50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Sandhill Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.